IVME Stock Overview
In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
In Veritas Medical Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.01 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | -98.00% |
| 3 Month Change | n/a |
| 1 Year Change | -96.67% |
| 3 Year Change | -99.44% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IVME | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | -3.5% |
| 1Y | -96.7% | 2.2% | 20.2% |
Return vs Industry: IVME underperformed the US Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: IVME underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| IVME volatility | |
|---|---|
| IVME Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVME's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IVME's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | G. Cooper | n/a |
In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company’s other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications.
In Veritas Medical Diagnostics, Inc. Fundamentals Summary
| IVME fundamental statistics | |
|---|---|
| Market cap | US$8.60k |
| Earnings (TTM) | -US$3.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IVME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVME income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.13m |
| Earnings | -US$3.13m |
Last Reported Earnings
Jan 31, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IVME perform over the long term?
See historical performance and comparison